# Levothyroxine-sodium Bioequivalence Trial With Oral Single Dose Administration

> **NCT06547242** · PHASE1 · COMPLETED · sponsor: **Berlin-Chemie AG Menarini Group** · enrollment: 132 (actual)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** Levothyroxin
- **DRUG:** Levothyroxin

## Key facts

- **NCT ID:** NCT06547242
- **Lead sponsor:** Berlin-Chemie AG Menarini Group
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-10-22
- **Primary completion:** 2022-03-22
- **Final completion:** 2022-05-22
- **Target enrollment:** 132 (ACTUAL)
- **Last updated:** 2024-08-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06547242

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06547242, "Levothyroxine-sodium Bioequivalence Trial With Oral Single Dose Administration". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06547242. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*